Drug Profile
INCB 15050
Alternative Names: INCB15050Latest Information Update: 12 Oct 2015
Price :
$50
*
At a glance
- Originator Incyte Corporation
- Class Antivirals
- Mechanism of Action CCR5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 12 Oct 2015 Discontinued - Phase-I for HIV infections in USA (PO)
- 09 Jan 2007 Phase-I clinical trials in HIV infections in USA (PO)
- 12 Jul 2006 Preclinical trials in HIV infections in USA (unspecified route)